Profile data is unavailable for this security.
About the company
Lotus Pharmaceuticals, Inc. (Lotus) develops, manufactures, and sells pharmaceuticals in the China. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. It operates, controls and owns the pharmaceutical businesses in China of Beijing Liang Fang Pharmaceutical Co., Ltd. (Liang Fang) and Beijing En Zhe Jia Shi Pharmaceutical Co., Ltd. (En Zhe Jia), collectively Lotus East. Lotus East is engaged in the production, trade and retailing of pharmaceuticals, focusing on the development of medicines and investing in strategic growth to address various medical needs. Lotus East owns and operates 10 drug stores throughout Beijing, China that sell Western and traditional Chinese medications, and generate revenues from the leasing of retail space to third party vendors in its retail stores.
- Revenue in USD (TTM)70.79m
- Net income in USD1.72m
- Incorporated2004
- Employees233.00
- LocationLotus Pharmaceuticals Inc16 Cheng Zhuang Road, Feng Tai DistrictBEIJING 100071ChinaCHN
- Phone+86 1 063899868
- Fax+86 1 063899867
- Websitehttp://www.lotuspharma.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imunon Inc | 0.00 | -19.51m | 12.50m | 33.00 | -- | 0.9338 | -- | -- | -2.17 | -2.17 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -59.23 | -50.18 | -80.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Monopar Therapeutics Inc | 0.00 | -8.40m | 12.69m | 10.00 | -- | 1.94 | -- | -- | -0.612 | -0.612 | 0.00 | 0.3749 | 0.00 | -- | -- | 0.00 | -81.69 | -54.07 | -107.13 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.62m | 12.87m | 85.00 | -- | 0.4698 | -- | -- | -3.01 | -3.01 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -44.86 | -58.80 | -48.21 | -66.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.08 | -- | 16.04 | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 12.99m | 5.00 | -- | 2.95 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| NanoViricides Inc | 0.00 | -9.36m | 13.31m | 7.00 | -- | 1.15 | -- | -- | -0.8004 | -0.8004 | 0.00 | 0.9828 | 0.00 | -- | -- | 0.00 | -55.47 | -43.54 | -57.90 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Actavia Life Sciences Inc | 0.00 | -4.44m | 13.35m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Lotus Pharmaceuticals Inc | 70.79m | 1.72m | 13.47m | 233.00 | 0.0904 | 0.0014 | 3.49 | 0.1903 | 0.0553 | 0.0553 | 2.56 | 3.58 | 0.6321 | 37.27 | 17.85 | 303,836.90 | 1.55 | 22.84 | 1.71 | 26.40 | 35.10 | 41.62 | 2.45 | 19.93 | 0.4428 | 30.80 | 0.0516 | 0.00 | 28.71 | 31.70 | -12.22 | 51.11 | 70.48 | -- |
| Kiora Pharmaceuticals Inc | 0.00 | -13.04m | 13.48m | 12.00 | -- | 0.6474 | -- | -- | -2.98 | -2.98 | 0.00 | 0.7929 | 0.00 | -- | -- | 0.00 | -77.27 | -70.52 | -91.06 | -81.86 | -- | -- | -- | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Dominari Holdings Inc | 2.04m | -22.88m | 13.65m | 26.00 | -- | 0.2579 | -- | 6.69 | -4.44 | -4.44 | 0.3899 | 8.92 | 0.0305 | -- | 0.3829 | 78,423.08 | -34.20 | -26.82 | -35.10 | -27.45 | -- | -- | -1,122.22 | -3,353.52 | -- | -- | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.70m | 46.00 | -- | 0.5121 | -- | 0.3201 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Nexgel Inc | 4.09m | -3.16m | 13.83m | 19.00 | -- | 2.71 | -- | 3.38 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Microbot Medical Inc | 0.00 | -10.74m | 14.11m | 22.00 | -- | 2.55 | -- | -- | -1.08 | -1.08 | 0.00 | 0.3845 | 0.00 | -- | -- | 0.00 | -120.24 | -53.28 | -178.87 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors Ltd.as of 29 Feb 2024 | 7.35m | 26.41% |
